Traumatic Brain Injury - Pipeline Review, Q2 2011

Date: April 1, 2011
Pages: 105
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T7D71BD8CB6EN
Leaflet:

Download PDF Leaflet

Traumatic Brain Injury - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, Q2 2011', provides an overview of the Traumatic Brain Injury therapeutic pipeline. This report provides information on the therapeutic development for Traumatic Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury. 'Traumatic Brain Injury - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Traumatic Brain Injury.
  • A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Traumatic Brain Injury pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Traumatic Brain Injury therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Traumatic Brain Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Traumatic Brain Injury
Traumatic Brain Injury Therapeutics under Development by Companies
Traumatic Brain Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Traumatic Brain Injury Therapeutics - Products under Development by Companies
Traumatic Brain Injury Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Traumatic Brain Injury Therapeutics Development
Abbott Laboratories
Sangart, Inc.
Alseres Pharmaceuticals, Inc.
Acorda Therapeutics, Inc.
Oxygen Biotherapeutics, Inc.
Proneuron Biotechnologies, Inc.
Neuren Pharmaceuticals Limited
Transition Therapeutics Inc.
Allon Therapeutics Inc.
Stem Cell Therapeutics Corp.
axxonis Pharma AG
M et P Pharma AG
D-Pharm Ltd.
KeyNeurotek Pharmaceuticals AG
Xytis Inc.
vasopharm GmbH
Innogene Kalbiotech Pte Ltd.
Maas Biolab
M's Science Corporation
NeuroHealing Pharmaceuticals Inc.
Sinapis Pharma, Inc
BHR Pharma, LLC.
Cognosci, Inc.
Traumatic Brain Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Anatibant - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Inosine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NBT-723 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ProgestoMat - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
DP-b99 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Oxycyte Emulsion - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Kalsolac - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
VAS203 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GGF2 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
KN38-7271 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NH001 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MC116 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MC113 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NNZ-2566 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vaprisol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rosuvastatin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Minocycline - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Recombinant Human Growth Hormone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Atorvastatin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Premarin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NeuroSTAT - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Methamphetamine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Autologous Stem Cell - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Epoetin Alfa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MP4OX - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
TT-301 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NimoGel - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BHR-100 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
AL-209 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
IM Risperidone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Darbepoetin Alfa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sodium Lactate - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Botulinum Toxin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Progesterone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mifepristone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Perfalgan - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Cop-1 Neuroprotective Vaccine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
EG-1964 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
COG1410 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SLV 334 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Nerve Growth Factor - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gabapentin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Autologous Human Umbilical Cord Blood Transplantation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ntx-428 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Plasmalyte A - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Traumatic Brain Injury Therapeutics – Drug Profile Updates
Traumatic Brain Injury Therapeutics - Discontinued Products
Traumatic Brain Injury - Featured News
Mar 03, 2011: Neurovive And The European Brain Injury Consortium Sign TBI Clinical Trial Collaboration
Mar 02, 2011: Oxygen Biotherapeutics Receives US Army Grant For Studies Of Oxycyte Perfluorocarbon Emulsion
Jan 05, 2011: UTHealth Studies Cord Blood Stem Cells For Pediatric Traumatic Brain Injury
Dec 08, 2010: Stem Cell Therapeutics Wins US Patent Relating To NTx-265
Dec 06, 2010: NeuroVive Obtains US Orphan Drug Designation For NeuroSTAT For Traumatic Brain Injury
Oct 12, 2010: Stem Cell Therapeutics Receives Request For Full TBI Proposal From US Department Of Defense
Oct 11, 2010: NeuroVive Receives European Orphan Drug Designation For NeuroSTAT For Treatment Of Traumatic Brain Injury
Oct 06, 2010: Sangart, Inc. Receives $1.1 Million Grant Award From The United States Department Of Defense For Further Development Of MP4 Molecule In Trauma
Sep 23, 2010: Oxygen Biotherapeutics Receives DSMB Approval To Proceed To Next Cohort In Phase IIB Clinical Trial For Traumatic Brain Injury
Sep 20, 2010: Athersys Reports Data Showing Neuroprotective Effects Of MultiStem Therapy For Traumatic Brain Injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 105

LIST OF TABLES

Number of Products Under Development for Traumatic Brain Injury, Q2 2011
Products under Development for Traumatic Brain Injury – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Abbott Laboratories, 2011
Sangart, Inc., 2011
Alseres Pharmaceuticals, Inc., 2011
Acorda Therapeutics, Inc., 2011
Oxygen Biotherapeutics, Inc., 2011
Proneuron Biotechnologies, Inc., 2011
Neuren Pharmaceuticals Limited, 2011
Transition Therapeutics Inc., 2011
Allon Therapeutics Inc., 2011
Stem Cell Therapeutics Corp., 2011
axxonis Pharma AG, 2011
M et P Pharma AG, 2011
D-Pharm Ltd., 2011
KeyNeurotek Pharmaceuticals AG, 2011
Xytis Inc., 2011
vasopharm GmbH, 2011
Innogene Kalbiotech Pte Ltd., 2011
Maas Biolab, 2011
M's Science Corporation, 2011
NeuroHealing Pharmaceuticals Inc., 2011
Sinapis Pharma, Inc, 2011
BHR Pharma, LLC., 2011
Cognosci, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Traumatic Brain Injury Therapeutics – Drug Profile Updates
Discontinued Products 97

LIST OF FIGURES

Number of Products under Development for Traumatic Brain Injury, Q2 2011 11
Products under Development for Traumatic Brain Injury – Comparative Analysis, Q2 2011 12
Products under Development by Companies, Q2 2011 13
Products under Investigation by Universities/Institutes, Q2 2011 15
Late Stage Products, Q2 2011 18
Mid Clinical Stage Products, Q2 2011 19
Early Clinical Stage Products, Q2 2011 20
Discovery and Pre-Clinical Stage Products, Q2 2011 21
Assessment by Monotherapy Products, Q2 2011 38
Assessment by Route of Administration, Q2 2011 39
Assessment by Stage and Route of Administration, Q2 2011 40
Assessment by Molecule Type, Q2 2011 41
Assessment by Stage and Molecule Type, Q2 2011 42
Traumatic Brain Injury - Pipeline Review, Q4 2010 US$ 450.00 Dec, 2010 · 64 pages
Traumatic Brain Injury - Pipeline Review, H2 2014 US$ 1,800.00 Oct, 2014 · 240 pages
Acute Spinal Cord Injury - Pipeline Review, Q4 2010 US$ 450.00 Dec, 2010 · 46 pages
Acute Spinal Cord Injury - Pipeline Review, Q2 2011 US$ 450.00 Apr, 2011 · 65 pages

Ask Your Question

Traumatic Brain Injury - Pipeline Review, Q2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: